Breast Cancer

Case summary:

Initials: M.R.G.

Age: 65

Sex: F

Cancer type and stage: Poorly differentiated infiltrating carcinoma of high degree of diffuse malignancy of non-special type (Inflammatory Carcinoma) of the left breast. Stage III.

Estrogen and progesterone receptors with Allred score of 3 or higher Her-2-neu with values of 0+ or 1+.

Localization of metastases: Possible metastases in right breast and pathologic nodes in right axilla. Suspicious right middle and lower pulmonary lobe nodules.

Date of diagnosis: late 2016.

Treatment and results before the start with LifEscozul™: M.R.G. had received chemotherapy for 5 months since diagnosis, 7 sessions, but it was not possible to reduce the tumor to be able to operate, so radiotherapy was indicated for 25 sessions and then surgery was performed in June 2017 (left mastectomy). In July 2017 she started oral chemotherapy. Despite this, in September 2017 she underwent a CT scan that showed apparent metastases in the lung.

Disease status and symptoms at the time of evaluation: headache and stomach pain. He was eating and sleeping well, with some depression.

Once the case was analyzed by our specialists, we informed the family members about what to expect with Escozul™ and the possibilities of achieving good results.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain a fluid communication with us, then the results with Escozul™ will not be as expected.

Start date with LifEscozul™: October 14, 2017, she was on oral chemotherapy with tumor progression.

Evolution, Follow-up and Current Results:

During the time of treatment, communication with M.R.G.'s family members has been fluid, which has allowed the necessary measures to be taken based on obtaining the best possible results. By December 1, 2017 we are told that she had a Mastography in the right breast and two lesions were seen and samples were taken for biopsies. The oncologist in her country increased the dose of oral chemotherapy. On our part, she was instructed to maintain the dose of Escozul™ until waiting for the result of the biopsy.

On December 12, 2017 they communicate that the biopsy result was positive for cancer in the two lesions of the right breast and in a right lymph node. They indicate that the surgeon wants to reduce the lesions to then operate and indicated a CT scan. At this time she was indicated to increase the dose of Escozul™ according to protocol.

On December 27, 2017 she communicates that she is with better appetite and does not vomit almost and without headache. The indications are maintained.

On January 18, 2018 she communicates that she has developed lesions in the left mastectomy scar with swelling of the left arm and that the oncologist thought it must be the tumor. She was evaluated by the surgeon and he told her that yes, it was the tumor on the left side that was affecting from the left armpit and he commented that he cannot operate that side and that to operate the lesions on the right breast she needs to perform intravenous chemotherapy to control that new lesion on the left side. He also sent results of general studies and the pending CT scan. The studies were generally well and the CT scan described a breast mass of 3.7 cm in the lower outer quadrant of the right breast with more than 7 left axillary nodes. Significant growth in number and size of pathological pericardial nodes with respect to the previous study. Nodules in right pulmonary hemifield compatible with metastasis. The dose of Escozul™ was increased due to the increase in size and number of nodes.

She communicates on February 25, 2018 and comments that she had studies done on February 21, 2018. She comments that the oncologist gave her good news at the consultation she had the week before and told her that she had responded well to the chemo and that she would tell her more. Her arm was quite reduced in swelling, although not all of it, she comments that she thinks it was due to the supplementation with Escozul™ which is doing her quite well and has also increased her appetite, she had lost two kilos in weight but in the last 15 days she has been eating very well.

On February 26, 2018 he sends the results of general studies which are all fine so the dose of Escozul™ is maintained.

He comments that the skin lesions are better.

On March 23, 2018 she indicates that the arm is now normal, she is eating well and is very well emotionally. She comments that she is sure that Escozul™ is doing a good job with her. She asks if Escozul™ potentiates the chemo and is told that they are independent treatments but that their combined effects can generate improvement as a final result.

On May 8, a new dose increase is indicated for the next treatment cycle according to protocol.

On July 11, 2018 he sends general results showing low Hemoglobin, Leukocytes and Platelets, possibly related to chemotherapy.

On August 26 he communicates that he is doing well, a venous line was placed and he was administered two chemo and a CT scan was performed. I am awaiting the result.

On September 3, 2018 she sends the result of a tomography of the skull, thorax, abdomen and pelvis performed last August 24, which indicates that there is no lesion in the surgical site of the left mastectomy and no other alterations of tumor type are described. She also comments that she is physically well, more active and eating well. She indicates that she is going to undergo general studies. The indications are maintained.

On September 5, 2018 she sends results of general studies that are normal. She comments that the oncologist is surprised by the results, she will indicate 4 more chemotherapy and that in November she will go into remission. She also comments that Escozul™ has been good. She requested a new cycle and it is indicated that she will be in remission and that she will continue treatment for 6 more months before discontinuing the treatment so in March 2019 it should conclude if everything continues like this or better.

In her contact of September 3 and indicates that she is physically well, more active and eating well.

Regarding the case of M.R.G. we can summarize that at the beginning of the treatment she was very symptomatic and in frank progress of the disease with involvement even of the right breast and later on the left surgical site.

Progressively there was a clinical improvement that was later accompanied by positive results in imaging studies where the lesions initially seen were not observed. These results are better than those normally obtained in similar cases, only with the use of conventional therapy. At this time there is no evidence of disease, which is an excellent result.

The family considers that Escozul™ has had a lot to do with his evolution.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors.

Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group November/2018

Medical Documents

M.M.O. is a 61-year-old patient, who came to us in October 2017 with a diagnosis of recurrent breast cancer with metastasis. The disease had started in 1989 where she had undergone surgery. She begins treatment with Escozul™ presenting with bone metastases in various locations and after 5 months of treatment, it is observed that the bone lesions described above have reduced in size and that some are even in the process of healing.

Summary of the case:

M.M.O. is a 61-year-old patient, who came to us in October 2017 with a diagnosis of recurrent breast cancer with metastasis. The disease had first been diagnosed and treated in 1989.

When we received the medical documentation we were able to ascertain that M.M.O. had a history of left breast cancer specifically a canalicular carcinoma diagnosed in 1989, treated with surgery and radiotherapy. The MRI performed in September 2017 showed the presence of tumor lesion in the sternum, anterior end of the first three left costal arches and adjacent soft tissues, as well as the circumference of the ipsilateral internal mammary artery.

Once the case had been analyzed by our specialists, we informed the patient's daughter about what to expect with Escozul™ and the possibilities of achieving good results. Generally in cases of breast cancer the results are usually positive, at least in terms of disease control.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

M.M.O started treatment with Escozul™ in October 2017, she was performing other natural treatments such as Kambó and later administration of enriched plasma.

Evolution, Follow-up and Current Results:

M.M.O.'s daughter has kept in contact with our specialists reporting the results of the different tests performed and the evolution of the patient, which according to referred by the relatives more or less a month after treatment, did not present any symptoms.

In a new MRI performed in March 2018, the size of the soft tissue mass and of the tumor lesions of the costal arches had decreased and the sternal lesion was healing.

In this case, despite the short time of treatment, we have achieved response of the disease to treatment, which we hope will be maintained and improved in future results.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group June/2018

Medical Documents

PP is a 39-year-old patient, who came to us in July 2017 with a diagnosis of advanced breast cancer, with multiple metastases. She has been on Escozul™ treatment for 3 months only but positive results have already started to be seen. *only first initials are mentioned at the patient's request, to protect her privacy*.

Case summary:

We share the case of a 39 year old female patient who came to us in July 2017, with a diagnosis of advanced breast with metastases in multiple locations.

When we received the medical documentation we were able to ascertain that PP presented with left breast cancer, specifically invasive ductal carcinoma, hormone dependent, with metastasis to axillary and retropectoral nodes, tumor mass in left adrenal gland and mass invading the proximal manubrium and sternum, with bone destructive changes and soft tissue involvement.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul™ and the possibilities of achieving good results. Although breast cancer generally has a good outlook with treatment, when it is in such advanced stages, it is difficult to know what to expect.

Each dose of Escozul™ is personalized, specific to the type of tumor and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

PP started treatment with Escozul™ the first days of August 2017.

Evolution, Follow-up and Current Results:

Although PP has been on treatment for a very short time, in this case the joint use of Escozul™ and chemotherapy has resulted in the patient having very good results, achieving reduction of all tumor lesions, as shown by the new CT scan performed at the end of September 2017. It shows that the mass in the left breast has decreased in size, as well as the axillary nodes on the same side. The mass invading manubrium/sternum appears sclerotic and soft tissue involvement disappeared. The mass in the left adrenal gland has decreased in size.

This is a preliminary result that at the moment implies an improvement in the evolution perspective of PP, with such an advanced disease. We hope that these results will be maintained and improved in future controls.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group September/2017

Medical Documents

Monica is a 50 year old patient, who was diagnosed with breast cancer in 2011 and operated in 2012, in 2015 presented relapse of the disease with pleural effusion, liver nodule and tumor involvement in bones. She received chemotherapy managing to stabilize the liver and bone lesions, although the pleural effusion continued to increase. He came to us in March 2017 looking for a treatment that would help him to counteract the disease seeing that chemotherapy only allowed to stabilize it.

Case summary:

We share the case of a 50-year-old female patient who came to us in March 2017, with a diagnosis of operated breast cancer with metastases to liver and bone and pleural effusion in progression. She is a patient who has been in treatment for a very short time, as she has just completed 3 months, but in such a short time very good results have been obtained, because in her last examination we can no longer see the tumors in bones, and she has decreased in size and the lesion in liver which also presents less tumor activity.

When we received the medical documentation we were able to confirm that Monica had been operated on for breast cancer (specifically a grade III infiltrating ductal carcinoma), after 3 years she was found to have pleural effusion, liver metastasis and bone metastasis in multiple locations. In spite of having continued receiving chemotherapy, the disease did not recede, although it had remained stable.

Once the case was analyzed by our specialists, we informed Monica about what to expect with Escozul™ and the possibilities of achieving good results.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Monica started treatment with Escozul™ in March 2017.

Evolution, Follow-up and Current Results:

Monica's case has had a very positive evolution in a short time, which is not the most frequent as we usually start to see results in the period of 3 to 6 months of starting the treatment.

 After 3 months of continuous treatment with Escozul™, we received a new PET-CT scan, where it is observed that the liver lesion has decreased in size and its metabolic rate (i.e. its tumor activity) has also decreased.

The bone lesions in the 7th and 10th costal arches are not observed, and the other bone lesions do not show tumor activity, they are considered benign.

Although very little time has passed since the beginning of the treatment, in this case the size and level of tumor activity of the hepatic nodule has been reduced and the bone tumor activity has been eliminated.

At this time Monica continues to be treated with Escozul™ with increasing doses, seeking to maintain the results obtained and help her to have a better quality of life and better life expectancy.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allows to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group July/2017

Medical Documents

Let's start with the description of the case:

She had a first relapse in 2014, of infiltrating lobular carcinoma, with lymph node involvement, which ended in a radical mastectomy, again managing to remove the affected areas. She contacted us in November 2015, in view of a new appearance of the disease, but this time in bones, with involvement of the spine.

Upon receiving Socorro's medical documentation, we were able to confirm that she had presented breast cancer on two occasions, specifically an infiltrating ductal carcinoma, which had metastasized in the spine from L3 to L5.

Once the case was analyzed by our specialists, we informed the patient about what they could expect with Escozul™ and the possibilities of achieving good results. In this case, we expected to at least stop tumor growth and prevent the appearance of new metastases.

Each dose of Escozul™ is personalized, specific to the type and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

Socorro started treatment with Escozul™ in early December 2015.

Results and evolution:

The results with Escozul™ in the first few months do not always go in a straight line. On many occasions, it is often observed that in those first three months the disease continues to progress and it is from the second trimester onwards that improvements are seen. In this case, the first examination we received from Socorro in January 2016, only 45 days after starting Escozul™, showed progression of the bone disease, involving T5 and T6 vertebrae. Despite this, Socorro continued with her normal life, without any pain.

The dose was readjusted to combat these new results.

In a new bone scan in April 2016, 4 months after starting treatment, we observed only bone involvement in L5, without describing other changes in other areas of the body, although we did observe a suspicious lesion of metastasis in the right tibia.

We again proceeded to increase the dose based on improving these results.

Subsequent examinations in October 2016, have shown that the bone scan is normal, all bone lesions have disappeared. This is a very good result, because in 11 months of using Escozul™, the disease has been eliminated.

We continue with a progressive increase in dosage, with the intention of maintaining these results and helping Socorro to live many more years free of cancer.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group November/2016

Medical Documents

Summary

Silvia is a 63-year-old patient who has been fighting breast cancer for 17 years. In February 2016 we were contacted by her daughter seeking treatment alternatives for her mom, who is in an advanced stage of the disease and receiving palliative chemotherapy.

We received Silvia's medical documents along with the report on her physical condition. Our team proceeded to analyze the case, in which we were able to establish that it is a breast cancer, specifically a grade II infiltrating carcinoma, diagnosed and treated for the first time 17 years ago with surgery on the right breast. It had relapsed in 2013 in the right breast and a new surgery was performed on the right breast. In the current examinations it could be observed that the patient presented tumor lymph node involvement in the left clavicle, multiple bone and pulmonary metastasis.

Regarding symptoms, we were informed that Silvia presented edema in the left arm, feeding difficulties, weight loss, cough and pain when inhaling (these last two symptoms conditioned by lymph node compression in the thorax).

The family was explained the results of the evaluation and Silvia's possibilities of achieving good results with the use of Escozul™ and what these could be. The dosage was prepared according to the patient's condition.

Silvia started treatment with Escozul™ at the beginning of March 2016, she was on palliative chemotherapy.

Current results:

For the follow-up of the case we took as reference the tumor marker CA15.3, taken in March two weeks after starting Escozul™, which was at 133.6 (normal value up to 25). Her CT scan at that time showed stable disease with respect to the last analysis in November 2015.

We received the first reports on Silvia's evolution in mid-April 2016. In terms of symptoms she was in good physical condition, she had regained weight.

As the chemotherapy had had no effect in reducing or eliminating lesions, Silvia started to receive only maintenance hormone treatment.

In July we received new test results from Silvia and an update on her symptoms. Her daughter told us that Silvia was physically very well, leading a normal life, and in very good spirits, without any of the symptoms she had before starting Escozul™.

Her blood tests were normal.

In August the antigen value had slightly decreased to 130.3. Already in September the CA value 15.3 was 117.

In October in a new update on Silvia's state of health, we are told that she is physically very well and leading a normal life.

In the tomography of January 2017, the pulmonary metastasis was stable, as were the bone metastases. After almost a year of treatment, the disease has remained stable and Silvia's quality of life has improved.

In the CT scan of August 2017, the disease remained stable without any progress.

We are awaiting the results of the next scan, but Silvia continues to do well, without any discomfort and is living a normal life.

In Silvia's case, the breast cancer has returned on more than one occasion and has been spreading in her organism, threatening her quality of life and survival. The use of Escozul™ has allowed Silvia to recover her quality of life and to have better prospects for fighting the disease.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, please fill in the form on our website: www.escozul-cuba.com and one of our specialists will be at your disposal.

Prepared by the LifEscozul™ Group.

Medical Documents

Initial Diagnosis:

Breast cancer (2008). Metastasis to lungs and liver, adenopathies in breast, hilum and mediastinum. Cervical lymphadenopathy.

Treatments received:

- Chemotherapy. Surgery.

Case analysis:

The case is evaluated by analyzing the type of cancer, its stage, aggressiveness, treatments applied and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent to the patient and his family.

Escozul™ is started in October 2012, with prescription of doses according to the progress of the disease and the patient's symptoms, which may be increased according to the results obtained in the patient, until the most effective dose is reached.

Escozul™ has the ability to selectively eliminate cancer cells without affecting healthy cells, which leads to the control of tumor growth and even to the reduction of tumors, besides helping to improve the patient's quality of life. It acts in many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of disease progression. (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/)

Current Results:

1. Tumors disappeared.
2. Good quality of life.

Summary:

During the treatment time, the dose of Escozul™ was increased to guarantee the good results obtained. The tumor parameters were lowered to normal levels, the patient remained stable, with good results in the blood tests and in the symptomatology.

The result is considered to be very positive, since many of the locations originally present have been eliminated, leading to an improvement in the patient's quality of life and an increase in his life expectancy. It should be emphasized that the contact between the patient and our medical team had a decisive influence in achieving these results, since it allowed adjustments to be made to the dose, which in turn had an impact on the disease.

\

Medical Documents

Patient:

Martha, 51 year old patient, came to us in January 2016, with a diagnosis of operated, metastatic breast cancer. After 4 years of struggle and constant chemotherapy without managing to contain the progression of the disease, Martha was given the task of looking for other alternatives that could offer her a chance to fight the cancer.

Diagnosis:

We received as usual the medical documents of the case and the patient's report on her physical condition. We proceeded to analyze the case, noting in the documents that it was a left breast cancer discovered at the end of 2010, specifically an infiltrating ductal carcinoma Grade III.

After receiving chemotherapies in 2011, she underwent surgery in 2012, finding lymph node tumor involvement and surgical edges. Since 2014, metastases were discovered in the left pleura.

Martha also presented progression of the disease to peritoneum, accompanied by ascites, having to undergo fluid drainage every 10 days. The tumor marker for breast cancer CA15-3 was at 42.2 (normal value up to 31).

Initial symptoms:

Martha told us that she felt abdominal pain, and experienced difficulty sleeping, significant weight loss, and felt depressed at times.

Treatments:

We proceeded to explain the situation to Martha and her possibilities of response with Escozul™, and with her consent, the dose was prepared so that she could begin treatment. According to the Escozul™ protocol, a high dose was prescribed to be increased according to the patient's evolution.

Martha started treatment with Escozul™ in February 2016, she was on palliative chemotherapy.

Current results:

During these 6 months of treatment, Martha's physical condition has improved considerably. She comments to us that she feels much better, and that she has gained weight from 38 kg in January to 62Kg at the moment.

The ascites, although not gone, has decreased, allowing the fluid to be removed twice a month, no longer every 10 days. This implies that there is less production of it by the tumor cells, or fewer tumor cells producing it. Although we do not have imaging tests to tell us how the disease is doing, the last CA15-3 antigen value is at 24.6 which is a significant decrease from January's value, as well as being within the normal range.

Martha has been undergoing chemotherapy for years, with no improvement in her symptoms or quality of life. Since she started Escozul™, the improvement in her physical condition has been noticeable, helping her to regain weight, energy and to fight the disease better. It is still a short time for us to see better results in such an advanced disease, but we hope Martha will continue to move forward

Conclusions:

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, scozul does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, please fill out the form on our website: www.escozul-cuba.com and one of our specialists will be available.

Medical Documents

Initial Diagnosis:

History of breast cancer with metastasis to bone in multiple locations, with predominance in spine and pelvis, since 2013.

Tumor markers: CA15-3=189.4, CA125=688.4, CEA=20.88 (carcinoembryonic antigen).

Initial symptoms:

• - hip discomfort
• - tiredness
• - dizziness
• - nausea

Treatments:

Started with Escozul™ at the beginning of October 2014. The patient had been undergoing chemotherapy and hormone therapy since 2013 when the disease was discovered, with partial results due to the appearance of new bone lesions and intensification of existing ones and increased tumor marker alores.

It is important to remember that Escozul™ is a natural product that has the ability to eliminate tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of work is done seeking that the patient can live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

From the first month of starting Escozul™, the patient referred that the nausea and dizziness caused by the chemotherapy disappeared and that the craving caused by the chemo drugs decreased considerably with respect to before taking Escozul™.

By December 2014 the tumor markers had started to decrease: CA15-3=185.9, CA125=539.2.

In March 2015 the markers were continuing to decrease: CA15-3=133.9, CA125=187.6 In April 2015, new PET-CT showed decrease in intensity of bone lesions and slight decrease in size of some lesions.

In June 2015, new decrease in tumor markers was seen: CA15-3=68.8, CA125=94.4.

In September 2015 antigen results were as follows: CA15-3=38.20, CA125=76.1, this time CEA=3.77 (normal value) was also measured.

In this case a continuous and marked decrease in the values of tumor markers has been achieved, evidencing a positive response to treatment with scozul, which had not been previously achieved with the joint administration of chemotherapy and hormone therapy. The values are increasingly closer to normal. The patient's quality of life has improved, the adverse effects of chemotherapy have decreased and the recovery time after chemotherapy has decreased. The fight is not over yet, but the results obtained so far are considered to be positive.

It is important to point out that it is not possible to generalize any result with Escozul™ in order to avoid creating false expectations in people. Each case we receive is analyzed in order to inform the family what to expect. Each person is a completely different universe, even if they have the same disease. This document is not a testimony but a summary of evolution where medical information is available for consultation.

Medical Documents

Case summary:

Breast cancer patient manages to stop tumor growth thanks to Escozul™.

Today we bring you the story of Irma who was diagnosed with breast cancer and came to us looking for an effective natural alternative against her type of cancer.

Case analysis:

This first step is essential, we realized the seriousness of it. Her initial diagnosis indicated that Irma suffered from a left breast cancer (mixed infiltrating carcinoma: ductal and lobular, estrogen and progesterone receptor positive) operated on, with recurrence in the right breast.

Unfortunately, it had also metastasized to bone in multiple locations (cranial vault, left clavicle, both shoulders and right humerus, costal arches of both hemithoraxes, right scapula, thoracic spine and thoracic spine).

thoracic spine and lumbar spine) and presented a pulmonary nodule and pleural effusion.

On analyzing his symptoms, we detected that he had little appetite, great difficulty in falling asleep and permanent bone pain. In general, his quality of life was not good.

Contact with the patient and his family:

Once the case was analyzed we went on to inform Irma and her family members what we thought Escozul™ could do in her case. A treatment protocol was designed focused on trying to stop the progression of the disease and improve her quality of life, for which a high dose-concentration was indicated, with gradual increases during the treatment.

She started with Escozul™ in April 2014 and was additionally on treatment with Tamoxifen, after having received radiotherapy to alleviate bone pain.

It is important to remember that Escozul™ is a natural product that has the ability to eliminate tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of work is done seeking that the patient can live with his disease with the least possible affectation to his daily routine.

Evolution and Current Results:

In the first report in June 2014, two months after starting treatment, the family reported that Irma was sleeping better, with more appetite, and that the pain decreased in intensity.

In September 2014, she underwent a CT scan of the chest, abdomen and pelvis which indicated that the disease had not progressed.

As of August 2015, reductions of some lesions began to be observed according to the CT scan performed on that date.

Finally, the last CT scan of the thorax, abdomen and pelvis, from December 2015, 1 year and 8 months after starting treatment, shows that the disease continues to be stable, with no increase in size of existing lesions or appearance of new lesions.

Irma has continued Escozul™ treatment with dose increases at least every 6 months, seeking to maintain and improve these results.

Summary of the case:

As can be appreciated Escozul™ in Irma's case has served as a brake to the disease, making it possible to improve her quality of life and extend her survival time.

In this case, it is worth highlighting the courage with which Irma faced and is facing her disease, the support of her family members and their constant concern to keep us informed.

It is important to point out that it is not possible to generalize any result with Escozul™ in order to avoid creating false expectations in people. Each case we receive is analyzed in order to inform the family what to expect. Each person is a completely different universe, even if they have the same disease.

This document is not a testimony but a summary of evolution where medical information is available for consultation.

Medical Documents

Case summary:

Escozul™: Patient with Breast Cancer, with presence of metastasis, remains stable after 3 years on treatment with Escozul™.

The patient we will talk about today has been on treatment with Escozul™ for 3 years, she is an advanced breast cancer with multiple metastases who has managed to control her cancer for three years using Escozul™ in conjunction with other therapies.

First contact:

In January 2013 we were written to by Marcia's brother, a 37 year old patient at the time, who had had breast cancer in 2009, being operated on and treated until she went into remission. Unfortunately in 2012 the disease reappeared in the bone (right femur), and by the beginning of 2013 metastases were found in other locations. Given the seriousness of this situation, her brother contacted us seeking to improve Marcia's quality of life.

Upon receiving the documentation of the case it was observed that Marcia had bone metastases in multiple locations and liver metastatic nodules, product of an invasive mammaductal carcinoma grade 3, stage IV. The grade of the cancer is not the same as the stage. Grade indicates how fast a tumor is likely to grow and spread. A Grade 3 tumor is considered a high-grade tumor that tends to grow and spread rapidly.

At that point she was experiencing severe bone pain and difficulty sleeping. She began treatment with Escozul™ in February 2013, at the same time as she began radiotherapy and chemotherapy treatment.

It is important to remember that Escozul™ is a natural product that has the ability to eliminate tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is carried out seeking that the patient can live with his disease with the least possible affectation to his daily routine.

Case analysis:

Given the aggressiveness of his type of cancer we set out to improve his quality of life and try to control exercise control over the growth of the different lesions. We established progressive doses of Escozul™ and periodic reevaluations. Marcia was told that we were going to focus on these objectives but that a fluidity of contact was needed to improve each dose of Escozul™.

Subsequent evolution and current results:

Once treatment began, Marcia took on the responsibility of staying in contact with us and keeping us updated regarding her evolution.

In July 2013, the disease was followed up through cervico-thoracic-abdomino-pelvic computed tomography (CT). It was observed that, although the same hepatic lesions persisted as in the January study, they had decreased in size. The bone lesions were stable.

At the one-year follow-up, the disease was stable, except for the appearance of a new bone lesion. Liver function tests were normal, as was the CA15-3 tumor marker value used for breast cancer, which in June 2013 was 36, above the normal value (31). Marcia maintained a good quality of life.

Given this situation, we continued with progressive increases in the concentration, seeking to decrease these lesions.

Marcia remained stable during 2014, with no disease progression and in good physical condition, despite the various treatments she was undergoing in stages.

In January 2015, in the control of the second year of treatment with Escozul™, two pulmonary nodules were observed in the CT scan, with small left pleural effusion. Liver and bone lesions remained of equal number and size. Liver tests were normal, although an increase in the CA15-3 value to 54 was observed. Despite this, Marcia reported feeling very well physically.

Progressive dose increases were continued, always seeking to control the progression of the disease, as it is an extremely aggressive cancer.

By June 2015, in a new CT scan the lung lesions had disappeared, although the pleural effusion persisted. A decrease in the number of liver lesions was also observed.

The antigen had dropped to 24, again within normal values. In the control at 3 years of treatment, the tumor marker CA15-3, was at 14, totally normal. Bone scintigraphy showed disappearance of bone lesions in two locations (rib and scapula), the other lesions remaining stable in size and most of them less intense than in the previous examination. CT scan showed mild pleural effusion, with no signs of malignant lesions in lung or pleura. In the liver the lesions appeared smaller in size.

Physically, Marcia comments that she feels well, that she has no pain anywhere, that occasionally she feels tired, although she associates it to the fact that she has an intense daily activity.

In a case of high-grade metastatic breast cancer, such as Marcia's, the progression of the disease is usually rapid and the deterioration of the patient is progressive. The fact that Marcia is doing better now than before she started treatment 3 years ago is a very good result, even though the disease has not gone away.

Marcia is physically well, lives a normal life, without limiting herself in her activities and continues to fight day by day to move forward with her family. Thanks to the communication she has maintained with our team of specialists, we have been able to adjust the treatment when necessary to obtain the best possible results.

It is important to note that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people. Each case we receive is analyzed in order to inform the family what to expect.

Each person is a completely different universe, even if they have the same disease. This writing is not a testimony but a summary of evolution where medical information is available for consultation.

To learn more about Escozul™, its effects and how to obtain it contact us at: servicios@lifescozulcuba.com

Medical Documents

Initial Diagnosis:

When she started Escozul™ she was on daily hormonal treatment and ibandronic acid every 3 months.

Treatments:

Right breast cancer operated in 2006, recurrence in 2009 with metastasis to liver and bones (right hip, vertebral body of L3, right sacroiliac joint).

Treatment with Escozul™:

Started with Escozul™ in August 2012, with a dose according to the type of cancer, degree of progression and physical condition of the patient.

Escozul™ has the ability to kill cancer cells without affecting healthy cells, leading to tumor growth control and even tumor shrinkage, as well as helping to improve the patient's quality of life. In cases of breast cancer we have good results in about 85% of the patients treated, with good results being understood as slowing down the disease, stopping its growth or reducing or eliminating tumors. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Evolution of the case and current results:

During the time of treatment the state of the disease has been monitored through bone scans and magnetic resonance imaging of the chest and abdomen, through which it has been observed that it has been possible to reduce the size of bone lesions and eliminate some locations, the same with liver lesions. The patient has remained stable, without symptoms and developing her normal life, living with cancer as a chronic and non-fatal disease.

Medical Documents

Initial Diagnosis:

Right breast cancer (infiltrating lobular carcinoma), with metastasis to axillary nodes. DHL=503 (used in cancer follow-up in general as elevated values may indicate proliferation of neoplastic cells in the body).

Initial symptoms:

• - Occasional pain
• - Difficulty with night rest
• - Anemia

Treatments:

Started on Escozul™ in early March 2015, she was undergoing chemotherapy treatment.

Escozul™ is a natural product that has the ability to kill tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

In April 2015, Maria del Carmen had her first control in terms of blood tests, in which the DHL value=459.7 was already decreased, closer to the normal value (414). The doctor reported that on palpation the breast tumor was reduced in size.

Five months after starting treatment with Escozul™, at the beginning of July, the patient's husband told us that the breast mass was no longer palpable. And that they were considering performing a preventive mastectomy anyway.

In August Maria del Carmen underwent a breast ultrasound in which it was confirmed that there was no presence of the disease.

At the end of August the surgery was performed, obtaining the result of the pathology which indicated that there was no residual tumor or neoplastic involvement in the removed breast tissue or axillary nodes.

María de Caren has continued to undergo the periodic check-ups established for these cases in her country.

To date, Maria del Carmen continues without signs of the disease.

The results obtained in this case are important, since, together with the chemotherapy, the size of the tumor decreased until it disappeared. It has also helped the patient to better withstand the side effects of chemotherapy, keeping her in good spirits and in good physical condition.

The results in this case demonstrate that the possibilities of eliminating the cancer are greater in cases in the initial stages, and that the administration of Escozul™ in conjunction with chemotherapy can be very positive not only in terms of symptom management but also in terms of obtaining results in a short time.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, please fill out the form on our website: www.escozul-cuba.com and one of our specialists will be available.

Medical Documents

Case summary:

Patient with bone metastasis from breast cancer with progressive decrease in tumor markers 11 months after starting treatment with Escozul™.

Initial Diagnosis:

History of left breast cancer in 2001 operated on. In March 2014 bone metastasis detected FA=181, CA27-29=232, CA15-3=130.3.

Treatments:

Started with Escozul™ in July 2014, he was undergoing chemotherapy treatment, after having received radiotherapy.

Escozul™ is a natural product that has the ability to kill tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

The first check-up was done in November, the patient's condition remained stable and the markers had started to go down: CA27-29=127, CA15-3=85.2, alkaline phosphatase also went down which is related in these cases with bone disease FA=131.

In December 2014 again there was a decrease in marker values: CA27-29=90.5, CA15-3=66.9.

A retest in January yielded the following tumor marker results: CA27-29=83.8, CA15-3=64.8.

At the end of March, chemotherapy was stopped due to catheter infection and clot formation.

In spite of this, in May the mammary antigen CA15-3=47.9 was repeated. The tests in June, which is the date of the last re-evaluation, had the following results: CA27-29=40.3 (normal value 38), CA15-3=33.8 (normal 28).

The patient is stable with no symptoms of disease progression, the result of the next comparative scan is awaited, to identify the status of the lesions with respect to the beginning of treatment.

Evolution and current results:

The results obtained in this case are important, by achieving a progressive decrease in tumor activity in the organism, which is reflected in the constant decrease in the values of tumor markers. No symptoms of deterioration have been observed in the patient's body, and her physical condition remains stable.

Medical Documents

Case summary:

Patient with metastatic operated breast cancer with stable disease and good quality of life after one year of treatment with Escozul™.

Initial Diagnosis:

History of operated breast cancer (mixed ductal and lobular infiltrating carcinoma). Metastasis to liver and multiple bone metastasis. Ca15-3=38 (breast antigen).

Treatments:

Started on Escozul™ in May 2014, had undergone surgery in late 2013 and was on hormonal treatment. Started radiation therapy for bone lesions in June 2014.

Escozul™ is a natural product that has the ability to kill tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

From the first week of treatment the patient described a noticeable improvement in her mood, feeling greater predisposition to daily activities.

At the July control, two months after starting treatment, she had not been able to stop the disease or control the CA15-3 which increased to 65, so the dose of medication was continued to be increased.

At the next control in November 2014, we had already managed to decrease the lesions in the liver below the initial size in May 2014, the bone lesions remained stable. The CA15-3 had decreased to 45.

At controls in February 2015 the CA15-3 had decreased to 27.5 very close to the normal value (25). A new decrease in the size of the liver lesions and stability of the bone lesions was observed.

The patient reports feeling in good physical condition and in good spirits.

In the last chest, abdomen and pelvis CT scan with contrast, at the beginning of June 2015, one year after treatment, the lesions in both liver and skeleton remain stable, without any change. The disease is under control. The patient is well, in good physical condition, she continues consuming Escozul™ with doses that increase progressively in order to maintain these results and to improve them.

The results obtained in this case are important, as the disease remains stable and the patient maintains a good quality of life, living with the disease, without it affecting her daily activities or physical performance.

The medical information is available for consultation at: www.escozul-cuba.com/resultados

Medical Documents

Initial Diagnosis:

CA right breast (moderately differentiated infiltrating ductal carcinoma, vascular permeation, stromal fibrosis (cirrhous carcinoma) (2011). Right axillary adenopathy.

Patient's condition before starting treatment:

• Pain in affected area.

Treatments received:

- Surgery, chemotherapy, radiotherapy.

Case analysis:

We proceed to evaluate the case by analyzing the type of cancer, its stage, aggressiveness, treatments applied and response. The physical and psychological condition of the patient is also taken into account.

Escozul™ is started in July 2012, with doses prescribed according to the progression of the disease and the patient's symptoms.

Escozul™ has the ability to selectively eliminate cancer cells without affecting healthy cells, leading to tumor growth control and even tumor shrinkage, as well as helping to improve the patient's quality of life. It acts on many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of disease progression. (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/)

Current Results:

• - Improved appetite
• - No pain
• - Good mood

Summary:

During the time of treatment the patient has been kept stable with a significant increase in his quality of life, the risks in the surgery have been reduced and it was possible to perform the surgery without consequences.

The result is considered very positive, since we have managed to keep the tumor under control, which leads to an improvement in the patient's quality of life and to an increase in his life expectancy. It should be emphasized that the contact between the patient and our medical team had a decisive influence in achieving these results, since it allowed adjustments to be made to the dose, which in turn had an impact on the disease.

Case summary:

Mirta, 31 years old, was diagnosed with a breast cancer and node metastasis that had been operated on. She was later found to have generalized metastasis to the liver, and bone metastasis to the skull.

He contacted us in October 2015, in search of an alternative option that would allow him to improve the prognosis of the disease.

We proceeded to the analysis of the available medical documentation, where we could verify that Mirta had undergone radical mastectomy with lymph node emptying in August 2015, finding metastasis in all the nodes removed. Subsequently in October 2015, multiple liver metastases were detected, and bone metastases in cranial calotte, spine and left scapula.

Treatment with Escozul™:

The results were discussed with the family and it was decided to start treatment with a high dose, looking for a quick and effective response that would allow Mirta to control the disease and improve her chances and survival time.

Mirta started with Escozul™ in November 2015, she had been doing chemotherapies for a couple of weeks.

Evolution, Follow-up and Current Results:

We received Mirta's first report in January 2016. In the CT scan performed, it was observed that the liver lesions were stable, no new lesions were observed. Her physical condition remained stable as well.

Progressive dose increases were continued, seeking to maintain and improve these results.

In March, Mirta remained unchanged.

In July we received a new update on the case. In the new CT scan dated June 30, 2016, the liver is noted to be smaller in size, and some of the liver metastases have decreased in size. The rest of the lesions are unchanged. At the cerebral level, the bone metastases in the cranial calotte have disappeared.

Currently, it is still considered that Mirta is still facing an advanced stage of the disease due to the extensive tumor involvement in the liver. However, in these 7 months of treatment she has been able to eliminate the bone lesions and reduce the size of the hepatic involvement acquiring quality of life. There is still a long way to go but we have advanced in the right direction.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated by our specialists please contact us at: servicios@lifescozulcuba.com . If you would like to learn more about Escozul™ and our work you can find information on this website.

Medical Documents

Treatments received:

Patient rejected conventional treatment options including surgery and opted to seek alternative options, started on Escozul™ in March 2014.

Escozul™ has the ability to kill cancer cells without affecting healthy cells, leading to tumor growth control and even tumor shrinkage, as well as helping to improve the patient's quality of life.

Current results:

After one year of treatment, the disease remains stable with a slight increase in two small nodules, with no spread of the disease outside the breasts and no new lesions appearing.

She maintains a good quality of life and is able to carry out all her normal activities.

Medical Documents

Case summary:

Patient with a Breast Cancer with presence of metastasis achieves disease shrinkage with the joint use of Escozul™ and chemotherapy.

Initial Diagnosis:

History of breast cancer 7 years ago operated, at the time of evaluation presented metastasis in liver (multiple nodules up to 19mm), bone and local recurrence (at site of operation). Prognosis of 18 months survival.

Treatments:

He was started on Escozul™ in May 2015. Had started chemotherapy in April 2015. It is important to remember that Escozul™ is a natural product that has the ability to eliminate tumor cells, without meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is carried out seeking that the patient can live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

Three months after starting treatment with Escozul™ in conjunction with chemotherapy, CT scans of the thorax, abdomen and pelvis show that local recurrence disappeared, the number of lesions in the liver decreased and their size decreased, the largest being 7mm (previously 19mm) and bone metastases remain stable.

Susana continued to improve gradually, with better results in each new control.

In the last studies received dated July and August 2017, after 2 years in treatment with Escozul™, it is observed that the lesions in bones have remained stable, without progression, and that there is no presence of the disease in any other location in the organism.

The patient has maintained a good quality of life. The administration of Escozul™ together with chemotherapy, has been beneficial for the patient, obtaining good results from the beginning of the treatment and achieving at this moment that the disease is diminished and controlled, improving Susana's expectations of survival.

Currently, she continues taking Escozul™ with progressive doses in order to maintain and improve these results.

It is important to point out that it is not possible to generalize any result with Escozul™ in order to avoid creating false expectations in people. Each case we receive is analyzed in order to inform the family what to expect. Each person is a completely different universe, even if they have the same disease. This document is not a testimony but a summary of evolution where medical information is available for consultation.

Medical Documents